Technology · Software - Services · Synthos Deep Dive · 2026-07-03
| Verdict | Buy — Core — systematic Synthos tier |
| Price (2026-07-02) | $188.35 · market cap ~$24.7B |
| Synthos scores (0–10) | Downside Risk 4 · Growth Quality 7 · Exponential Potential 3 |
| Synthos fair value (base case) | ~$208 → +10% · full range $144 (bear) – $248 (bull) |
| Street consensus | $226 (high $260 / low $185; 1 Strong Buy · 8 Buy · 15 Hold · 1 Sell — consensus Hold) — context, not our anchor |
| Valuation | 28.6× trailing EPS · 24.6× FY26E · 21.7× FY27E · 15.3× FY30E · EV/S 9.3× · EV/EBITDA 17.2× |
| Exponential Potential | 3/10 · Low — ~6.5% revenue CAGR that is not accelerating; EPS growth is largely buyback-driven; mature TAM |
| Technicals | Downtrend — $188, −39% off 52-wk high, below the 200-DMA, RSI 57, −40% 12-mo (SPY +21%) |
| Conviction | Low breadth — 0 expert voices in the KB; call rests on fundamentals + quant |
| Position sizing | Watch-list; a starter ≤1–2% only on a deeper pullback or a re-acceleration signal |
| Next catalyst | 2026-07-29 Q2'26 earnings (Street EPS $1.95, revenue ~$804M) |
| Single biggest risk | A single-segment (P&C insurance analytics) business paying up for slow growth — de-rating risk if the ~7% growth ever wobbles |
One-line thesis. Verisk is a genuinely elite, wide-moat data monopoly on U.S. property-and-casualty insurance (67% gross margin, 54% EBITDA margin, ~29% return on invested capital) — but it grows revenue only ~6.5% a year, the stock still trades at ~28× trailing earnings after a brutal 40% drawdown, and there is no expert conviction behind it in our KB, so it earns a Watch, not a buy, until either the price or the growth rate improves.
Verisk is the company almost every U.S. home-and-car insurer quietly pays to help decide how much to charge you and whether a claim is legit. It owns decades of insurance data nobody else has, so insurers basically have to buy from it — that's a fantastic, sticky business that keeps about 29 cents of profit out of every sales dollar.
The catch is two-fold. First, it's a slow grower — sales rise only about 6–7% a year, which is fine but not exciting. Second, even after the stock fell about 40% over the past year, it's still not cheap — you pay roughly $28 for every $1 of annual profit. Great company, full-ish price, slow growth, and no expert on our panel banging the table for it. So our verdict is Watch — keep it on the list, but wait for a better entry price or proof it can grow faster.
Here's what our three scores mean in everyday terms:
The one big worry: Verisk is now a one-trick pony — it sold off its energy and financial-services arms, so it lives or dies on U.S. insurance analytics. If that ~7% growth ever stalls, a stock this richly priced has room to fall further.
Solid = price · dashed = 50-day average · dotted = 200-day average · amber = 52-week high/low. Price above both averages is an uptrend.
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Above 70 (red band) = overbought, below 30 (green band) = oversold. Currently 61.
Blue crossing above amber (bars flip green) = momentum turning up; below (bars red) = turning down. Bar height = the size of that gap.
Solid = VRSK · dashed = S&P 500 · dotted = XLK (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Every claim reconciles to a real claim_id in the Synthos knowledge base — this is the evidence the verdict is built on, not vibes. Management (the company itself) is shown but half-weighted; one cautionary voice is included on purpose.
Verisk Analytics (NASDAQ: VRSK) is a Jersey City–based data-analytics company, founded 1971, that sells predictive models, risk scores, and decision tools primarily to the U.S. property-and-casualty (P&C) insurance industry — rating, underwriting, catastrophe/weather modeling, claims and anti-fraud analytics. Its data assets (industry-pooled loss data, ISO rating information, catastrophe models) are effectively a regulatory-grade utility: insurers file rates built on Verisk's data with state regulators, which makes the product deeply embedded and recurring (subscription/long-term contracts). Fiscal year ends December 31; CEO Lee Shavel; ~7,800 employees.
Important structural note — Verisk is now essentially a pure-play. Over 2022–2023 Verisk divested its Energy & Specialized Markets and Financial Services segments to become a focused insurance-analytics company. That shows up in the data: FMP's product segmentation reports only an "Insurance" segment from FY2023 onward (the FY2025 "Insurance" line of $2.18B appears to be a partial/mislabeled sub-total; the audited FY2025 total revenue is $3.07B — use the consolidated income statement, not the segment line). Treat VRSK as a single-segment business.
Revenue mix (FY2025, from filings):
There is no expert coverage of VRSK in the Synthos knowledge base: total_claims = 0, breadth 0, net conviction 0. No net-bullish or cautionary voice in our distilled panel has spoken on this name, so there is no traceable claim_id to cite, and we will not manufacture one. Honesty is the product: this verdict is fundamentals- and quant-driven only.
What that means in practice: the bull/base/bear below rest entirely on (a) the reported financials, (b) live FMP analyst consensus (labeled as estimates), and (c) our own valuation model — with none of the extra conviction weight a broad expert panel would add. A name with a genuinely elite moat but zero independent conviction and a slow growth rate is exactly the kind of name that belongs on a Watch list rather than in a high-conviction buy sleeve.
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
| Score | 0–10 | The read |
|---|---|---|
| Downside Risk (lower = safer) | 4 · Low–Moderate | Beta 0.70 and a recession-proof, subscription-based utility model make it structurally sturdy; against that, 28.6× trailing on ~6.5% revenue growth is rich-for-the-growth, net-debt/EBITDA is 2.5× TTM (~1.7× on FY25 EBITDA), and single-segment concentration adds fragility. The 40% drawdown has already partly de-risked valuation. |
| Growth Quality | 7 · High | 67% gross margin, 54% EBITDA margin, ~29% ROIC, and a regulatory-grade moat — elite quality — but revenue compounds only ~6.5%, so it can't earn the 8–9 reserved for high-margin and fast-growing names. |
| Exponential Potential | 3 · Low | Mid-single-digit revenue growth that is not accelerating (FY26E +5% → FY30E +7%, roughly flat), a mature U.S. P&C TAM, and EPS growth that leans heavily on buybacks. No multibagger runway. |
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is by definition the expected path, so a weighted blend would just restate it with false precision. Instead the cases bound the range, and the scores above summarize them.
| Case | Key assumptions | Fair value |
|---|---|---|
| Bull | Pricing power + new AI/analytics modules re-accelerate organic growth toward high-single/low-double digits; FY27E EPS beats to ~$9.2 (vs $8.67 cons); the market re-rates the quality back toward ~27×. | ~$248 (+32%) |
| Base (our anchor) | Estimates roughly hit — FY27E EPS $8.67; a durable ~6–7% grower with elite margins holds a ~24× multiple (below its historical premium, reflecting the slower growth). | ~$208 (+10%) |
| Bear | Organic growth slips toward ~4%, a large insurer renegotiates, or the multiple keeps compressing toward the market; FY27E EPS ~$8.0 at a de-rated ~18×. | ~$144 (−24%) |
Synthos fair value = the base case, ~$208 (+10%), with the full $144–$248 span as the honest range. This anchor sits below the Street's $226 consensus — we are less willing than the sell-side to pay a premium multiple for ~6.5% growth. Note the Street itself is only lukewarm here: the grade consensus is Hold (15 Hold vs 9 Buy, 1 Sell). This is a tracked call — the Forecaster Scorecard grades it once it matures.
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). VRSK is a high-quality compounder with essentially no exponential character:
Exponential Potential: Low (3/10). Own it, if at all, for durable ~6–7% revenue compounding plus buyback-levered ~11–14% EPS growth and a fortress moat — not for acceleration. This is squarely a Core-quality-at-a-price name, and it is the reason the verdict is Watch rather than Buy.
VRSK is not cheap on an absolute basis (28.6× trailing EPS, 9.3× EV/sales, 17.2× EV/EBITDA) for a ~6.5% revenue grower — but it is far less demanding than a year ago after the ~40% drawdown. The forward path compresses the multiple: on live consensus P/E is 24.6× (FY26E) → 21.7× (FY27E) → 15.3× (FY30E) if estimates hit. The bull case is that an elite, regulatory-moated utility deserves a premium regardless of growth rate; the bear case is that ~28× trailing for ~7% growth is a PEG well north of 3, which the market has been steadily unwinding (hence the de-rate). Street targets (context): consensus $226, high $260, low $185; grade consensus Hold. Our $208 base-case fair value sits below consensus because we decline to pay up for slow growth. Verdict: a quality-at-a-fullish-price name — reasonable to own on a deeper pullback, not compelling here.
Verisk's moat is one of the widest in the S&P 500 software cohort: it is a data monopoly on U.S. P&C insurance. Insurers pool their loss experience into Verisk (ISO), Verisk turns it into rating/underwriting products, and insurers file rates with state regulators built on that data — a closed loop that is nearly impossible for a new entrant to replicate (you can't buy 50 years of industry-pooled loss data). Switching costs are high, contracts are long, and the product is mission-critical and regulatory-embedded. The trade-off for that fortress is a capped TAM — Verisk already dominates its niche, which is precisely why growth is only mid-single-digit.
Peer set (market cap) — imperfect comps: the closest analogs are the other data/analytics duopolists, Equifax $20.8B and TransUnion $15.1B (credit-data monopolies with similar moat character). FMP's remaining "peers" — EMCOR $34.5B, Hubbell $25.7B, Ingersoll Rand $31.5B, Old Dominion $45.3B, Rocket Lab $58.2B, United Airlines $43.3B, Veralto $22.7B, Wabtec $44.5B — are size-matched industrials/transports, not business-model comparables and should be ignored for valuation. Against EFX/TRU, VRSK carries the highest margins and the highest multiple.
Thesis tripwires (what would change the call): organic revenue growth printing below ~4% for two straight quarters (would push toward Avoid); or the stock reclaiming and holding above its 200-DMA on re-accelerating growth (would push toward Buy — Tactical).
Watch. Verisk is a genuinely elite, wide-moat data monopoly with top-decile margins and reliable free cash flow — but it grows revenue only ~6.5% a year, still trades at ~28× trailing earnings after a 40% de-rate, sits in a year-long technical downtrend below its 200-DMA, and carries no expert conviction in our KB. The base-case fair value (~$208, +10%) offers only modest upside and lands below the Street's own lukewarm Hold consensus. That combination — great business, full-ish price, slow growth, no conviction, broken chart — is the definition of a Watch, not a buy.
claim_id is cited and none was fabricated. The verdict is explicitly fundamentals- and quant-driven.